Press Releases

Press Releases

Applied Molecular Transport Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Corporate Update

Mar 09, 2023
Exploring strategic partnership options to advance AMT-101 for chronic pouchitis, an orphan indication with no  FDA-approved products Evaluating next steps for the company's second clinical asset, AMT-126 SOUTH SAN FRANCISCO, Calif., March 09, 2023 (GLOBE NEWSWIRE) -- Applied Molecular Transport
View

Applied Molecular Transport Presents Additional Data from Oral AMT-101 Phase 2 FILLMORE Trial in Chronic Pouchitis at ECCO ’23 Congress

Mar 03, 2023
New positive data demonstrate oral AMT-101’s gut-restricted profile with tissue-level pharmacodynamics (PD) effects and no systemic exposure by design Translational analysis reveals IL-10 biological responses in both 3mg and 10mg dose arms SOUTH SAN FRANCISCO, Calif., March 03, 2023 (GLOBE
View